Form 4: Supernus Pharmaceuticals Executive Exercises Options and Sells Shares
SEC Form 4 Filing
A Supernus Pharmaceuticals executive, Padmanabh P. Bhatt, exercised stock options and sold shares on December 3, 2024.
Summary
- Padmanabh P. Bhatt, a Senior VP of IP and CSO at Supernus Pharmaceuticals, engaged in multiple transactions involving the company's stock on December 3, 2024.
- Bhatt exercised options to acquire 8,750 shares at $23.99 and 12,745 shares at $25.30.
- Concurrently, Bhatt sold 8,750 shares at a weighted average price of $36.68, with individual sales ranging from $36.29 to $37.01.
- Additionally, Bhatt sold 12,745 shares at a weighted average price of $36.68, with individual sales ranging from $36.24 to $37.00.
- Following these transactions, Bhatt's direct holdings of Supernus common stock decreased to 9,679 shares.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It does not contain any information that would be considered positive or negative for the company's outlook.
Industry Context
This is a routine filing related to insider trading activity, which is common for executives who hold stock options. It does not indicate any specific trend in the pharmaceutical industry.
Comparison to Industry Standards
- Executive stock option exercises and sales are a common practice across publicly traded companies, including those in the pharmaceutical sector.
- The reported transactions are consistent with standard compensation practices and do not appear to deviate from industry norms.
- Companies like Amgen, Gilead, and Biogen also have executives who regularly exercise options and sell shares, and these transactions are typically disclosed through similar SEC filings.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the increased supply of shares in the market.
- The transactions do not have a direct impact on employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 02/24/2018 | The option for 12,745 shares vested in four equal annual installments beginning on this date. |
| 02/21/2021 | The option for 8,750 shares vested in four equal annual installments beginning on this date. |
| 12/03/2024 | Date of the stock option exercise and share sales. |
| 12/04/2024 | Date the SEC Form 4 was signed. |
Keywords
Supernus Pharmaceuticals, stock options, insider trading, SEC Form 4, equity securities, stock sale, Padmanabh P. Bhatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.